nach oben

Current Urology Reports

Erschienen in:

01.09.2018 | Prostate Cancer (S Prasad, Section Editor)

Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents

verfasst von: Sarah Bennett Starosta, Stephen J. Savage

Erschienen in: Current Urology Reports | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To update treatment options and considerations for castration-resistant prostate cancer with specific attention to sequencing of agents based on available evidence and treatment rationale.

Recent Findings

The newest research developments over the last several years include multicenter studies that address the sequencing of therapies to improve the treatment of metastatic castration-resistant prostate cancer. Chemotherapy agents, as well as androgen receptor antagonists, are evolving, and there are new tests available to define which patients are more likely to benefit. In addition, there have been some additional trials looking into the safety and efficacy of combination treatment and new therapies.

Summary

There are multiple factors that should be considered to determine the sequence and/or combinations of therapies for metastatic castration-resistant prostate cancer that can improve quality of life and survival. Promising novel agents in combination with personalized medicine will likely continue to improve treatment of these patients.

Noone AM, H.N., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, SEER Cancer Statistics Review, 1975–2015. based on November 2017 SEER data submission, posted to the SEER web site, April 2018. National Cancer Institute. Bethesda, MD, 2018.

Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10(10):e0139440. https://doi.org/10.1371/journal.pone.0139440.CrossRefPubMedPubMedCentral

Huggins C, Hodges CV. The effect of castration of estrogen and androgen injection on serum phosphatases and metastatic carcinoma of the prostate. Studies on Prostate Cancer. 1941;1(4):293–7.

Grayhack JT, Keeler TC, Kozlowski JM. Carcinoma of the prostate. Hormonal Therapy Cancer. 1987;60:589–601.PubMed

Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res. 2008;40(5):315–22. https://doi.org/10.1055/s-2008-1073142.CrossRefPubMed

Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605. https://doi.org/10.1200/JCO.2006.10.1949.CrossRefPubMed

Handy CE, Antonarakis ES. Sequencing treatment for castration-resistant prostate cancer. Curr Treat Options in Oncol. 2016;17(12):64. https://doi.org/10.1007/s11864-016-0438-9.CrossRef

Greenspan S, Coates P, Sereika S, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):410–6417. https://doi.org/10.1210/jc.2005-0183.CrossRef

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–18. https://doi.org/10.1056/NEJMoa1715546.CrossRefPubMed

10.

•• Crawford ED, Higano CS, Shore ND, Hussaini M, Petrylack DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194(6):1537–47. https://doi.org/10.1016/j.juro.2015.06.106. Great reivew of previous treatments CrossRefPubMed

11.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. https://doi.org/10.1056/NEJMoa040720.CrossRefPubMed

12.

Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5. https://doi.org/10.1200/JCO.2007.12.4008.CrossRefPubMed

13.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. https://doi.org/10.1056/NEJMoa041318.CrossRefPubMed

14.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54. https://doi.org/10.1016/S0140-6736(10)61389-X.CrossRefPubMed

15.

• Oudard S, Fizazi K, Sengeløv L, Daugaard G1, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 2017: 35(28): 3189–3197. Doi: https://doi.org/10.1200/JCO.2016.72.1068. Review of taxane chemotherapy role.

16.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015: 16(2): 1205–1207. Doi: https://doi.org/10.1016/S1470-2045(14)71205-7, 152, 160.

17.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33. https://doi.org/10.1056/NEJMoa1405095.CrossRefPubMedPubMedCentral

18.

Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus Bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016;34(18):2098–106. https://doi.org/10.1200/JCO.2015.64.9285.CrossRefPubMed

19.

Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung v OS, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153–63. https://doi.org/10.1016/S1470-2045(15)00518-5.CrossRefPubMed

20.

•• Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–56. https://doi.org/10.1200/JCO.2016.70. Good paper about the efficacy of novel androgen agents with splice variants. CrossRefPubMedPubMedCentral

21.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–38. https://doi.org/10.1056/NEJMoa1315815.CrossRefPubMedPubMedCentral

22.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncology. 2015;2015(1):582–91. https://doi.org/10.1001/jamaoncol.2015.1341.CrossRef

23.

Fizazi K, Albiges L, Loriot Y, Massard C. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015;15(9):1007–17. https://doi.org/10.1586/14737140.2015.1081566.CrossRefPubMedPubMedCentral

24.

Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975–85. https://doi.org/10.1016/S1470-2045(14)70240-2.CrossRefPubMed

25.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089–94. https://doi.org/10.1200/JCO.2005.04.5252.CrossRefPubMed

26.

Kantoff PW, Higano C, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. https://doi.org/10.1056/NEJMoa1001294.CrossRefPubMed

27.

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–7. https://doi.org/10.1200/JCO.2016.69.1584.CrossRefPubMed

28.

Kantoff PW, Scheutz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–105. https://doi.org/10.1200/JCO.2009.25.0597.CrossRefPubMedPubMedCentral

29.

Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9. https://doi.org/10.1158/1078-0432.CCR-04-2244.CrossRefPubMed

30.

Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406. https://doi.org/10.1016/S1470-2045(14)70474-7.CrossRefPubMed

31.

• Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, et al. Three-year safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial. Eur Urol. 2017;73(3):427–35. https://doi.org/10.1016/j.eururo.2017.06.021. Good follow-up about which patients should be considered for Radium treatment. CrossRef

32.

Shore ND, Tutrone RF, Mariados NF, Nordquist LT, Mehlhaff BA, Steere KJ, et al. eRADicAte: a prospective evaluation combining Radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer. Clin Genirourin Cancer. 2018;16(1):149–54. https://doi.org/10.1016/j.clgc.2017.10.022.CrossRef

33.

Saad F, Charles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2010;17(9):1306–3016. https://doi.org/10.1016/S1470-2045(16)30173-5.CrossRef

34.

Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016;43(1):8–20. https://doi.org/10.1007/s00259-015-3185-4.CrossRefPubMed

35.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46. https://doi.org/10.1016/j.urolonc.2016.12.021.CrossRefPubMedPubMedCentral

36.

Oudard S, Kramer G, Caffo O, Creppy L, Loriot Y, Hansen S, et al. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int. 2015;115(5):744–52. https://doi.org/10.1111/bju.12845.CrossRefPubMed

37.

Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. Eur J Cancer 2018: Doi: https://doi.org/10.1016/j.ejca.2018.03.008, 97, 41, 48.

38.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate. 2014;74(15):1544–450. https://doi.org/10.1002/pros.22872.CrossRefPubMed

39.

Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, et al. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014;12(5):167–72. https://doi.org/10.1016/j.clgc.2014.03.010.CrossRef

40.

Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92. https://doi.org/10.1016/S1470-2045(12)70379-0.CrossRefPubMed

41.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. https://doi.org/10.1056/NEJMoa1207506.CrossRefPubMed

42.

de Bono JS, Chowdhury S, Feyerabend T, Elliott T, Grande E, Melhem-Bertrandt A, et al. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe. Eur Urol. 2017;74:37–45. https://doi.org/10.1016/j.eururo.2017.07.035. CrossRefPubMed

43.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67(1):23–9. https://doi.org/10.1016/j.eururo.2014.06.045.CrossRefPubMed

44.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate. 2014;74(13):1278–95. https://doi.org/10.1002/pros.22844.CrossRefPubMedPubMedCentral

45.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. 2015;68(2):228–35. https://doi.org/10.1016/j.eururo.2014.04.015.CrossRefPubMed

46.

Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol. 2014;66(3):459–65. https://doi.org/10.1016/j.eururo.2013.11.044.CrossRefPubMed

47.

• Francini E, Fiaschi AI, Petrioli R, Bianco V, Laera L, Francini F, et al. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival. Anti-Cancer Drugs. 2015;26(8):910–1. https://doi.org/10.1097/CAD.0000000000000258. Options for heavily treated patients in this disease state. CrossRefPubMed

48.

Davies RS, Smith C, Lester JF. Third-line enzalutamide following docetaxel and abiraterone in metastatic castrate-resistant prostate cancer. Anticancer Res. 2016;36(4):1799–803.PubMed

49.

Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15(10):1147–56. https://doi.org/10.1016/S1470-2045(14)70303-1.CrossRefPubMed

50.

• Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, et al. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study. Eur Urol. 2015;68(1):147–53. https://doi.org/10.1016/j.eururo.2014.10.014. Also interesting information for patients who had failed multiple treatments. CrossRefPubMed

51.

Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP inhibitors in prostate Cancer. Curr Treat Options in Oncol. 2017;18(6):131–41. https://doi.org/10.1007/s11864-017-0480-2.CrossRef

52.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708. https://doi.org/10.1056/NEJMoa1506859.CrossRefPubMedPubMedCentral

Titel: Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents
verfasst von: Sarah Bennett Starosta
Stephen J. Savage
Publikationsdatum: 01.09.2018
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 9/2018
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-018-0826-8

Neu im Fachgebiet Urologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Urologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Urologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers

Management of Postoperative Lower Urinary Tract Symptoms (LUTS) After Pelvic Organ Prolapse (POP) Repair

Comparison of Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia

Costs of Managing Benign Prostatic Hyperplasia in the Office and Operating Room

Voiding Dysfunction After Non-urologic Pelvic Surgery

Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review

Neu im Fachgebiet Urologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Urologie